Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Bioequivalence of Lisdexamfetamine dimesylate 20 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 70 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fed Conditions.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fasting Conditions.
The George Institute
No medical condition.
1 trial -
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.
The George Institute
No medical condition.
1 trial -
Bioequivalence of One Tablet of Gliclazide MR 90 mg (S005190) and One and a Half Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.
The George Institute
No medical condition.
1 trial -
Bioequivalence of Ruxolitinib 20 mg Tablets in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Testosterone Transdermal Gel in Healthy Female Participants.
Laboratorios Tillomed Spain S.L.U
No medical conditions.
1 trial -
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition
1 trial -
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Vortioxetine 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions
Laboratorios Tillomed Spain S.L.U
No medical condition
1 trial -
Bioequivalence of Vortioxetine 5 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl
Alphapharm Pty Ltd
Bioequivalence trial in healthy volunteers
1 trial -
Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl
Alphapharm Pty Ltd
Bioequivalence trial in healthy volunteers
1 trial -
Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers
Orion Laboratories Pty.
Parkinson disease
1 trial -
Bioequivalence study 2 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers
Orion Laboratories Pty.
Parkinson desease
1 trial -
Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects
Orion Laboratories Pty.
short-term treatment of insomnia
1 trial -
Bioequivalence study of GP-IMP-001 with regards to reference product
Lacuna Pharma Pty Ltd
healthy volunteers
1 trial -
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative design
Helsinn Birex Pharmaceuticals
Healthy volunteers
1 trial -
Biological/Vaccine: therapeutic autologous dendritic cells.
LISATA THERAPEUTICS, INC.
Kidney Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources